| INTRODUCTION
Dogs with degenerative mitral valve disease (DMVD) are on a diverse spectrum of disease severity. The American College of Veterinary Internal Medicine consensus statement, heart disease severity grading scheme (ACVIM-HD) describes 4 stages of heart disease and failure in Abbreviations: ACVIM-HD, American College of Veterinary Internal Medicine consensus statement, heart disease severity grading scheme; bpm, beats per minute; CHF, congestive heart failure; CKCS, Cavalier King Charles Spaniel; cTnI, cardiac troponin I; DMVD, degenerative mitral valve disease; EPIC, Evaluation of Pimobendan In dogs with Cardiomegaly; EPR, electronic patient record; HR, hazard ratio; IQR, interquartile range; NT-proBNP, N-terminal pro B-type natriuretic peptide; PH, proportional hazards; SD, standard deviation; VetCompass, Veterinary Companion Animal Surveillance System. dogs with DMVD. 1 Stage A describes dogs at high risk of DMVD that are yet to develop structural heart disease (eg, dogs of breeds predisposed to DMVD that do not have heart murmurs). Stage B denotes the preclinical stages of DMVD, whereby dogs have heart murmurs as a result of mitral regurgitation but no current or previous history of congestive heart failure (CHF). Stages C and D describe dogs with DMVD that has progressed to CHF. Until recently, there has been no strong evidence for the benefit of treatment in dogs with stage B DMVD. Distinguishing between ACVIM-HD stages B1 (preclinical DMVD with a normal heart size) and B2 (preclinical DMVD with cardiac chamber enlargement), therefore, might not have altered the management of these cases. However, because the EPIC study reported the benefit of administering pimobendan to dogs with echocardiographic and radiographic evidence of advanced stage B2 disease, there is greater interest and clinical merit in identifying dogs with more advanced preclinical DMVD. 2 Previous observational studies and randomized controlled trials have evaluated factors associated with disease progression in dogs with stage B DMVD. [2] [3] [4] [5] [6] [7] [8] Natriuretic peptides, 3, 4, 6 radiographic and echocardiographic measurements, [2] [3] [4] [5] 7 presenting signs and physical examination findings, 2,5-8 age, 7 systolic arterial blood pressure, 2 and pimobendan treatment 2 have been reported to be associated with outcome in dogs with preclinical DMVD. However, the samples of dogs included in these studies were restricted to those attending teaching or referral hospitals or a single breed. These samples might be poorly representative of the spectrum of dogs with preclinical DMVD attending primary care veterinary practice. Furthermore, prognostic factors measured by specialist veterinary cardiologists might not be clinically useful in primary care practice, where the level of expertise and availability of equipment required to obtain these measurements might not match those found in referral centers. 9 Prognostic factors that can be readily measured in the primary care setting could help first opinion veterinarians assess the likely disease severity in dogs with preclinical DMVD. The ability to do so could aid prognostication when evaluating the likely outcome for a dog and identify those dogs that might benefit most from frequent monitoring, diagnostic imaging, or evaluation by a veterinary cardiologist.
Our aim was to prospectively follow dogs presumed to have stage B DMVD and to evaluate whether key measurements were associated with disease progression in the UK primary care setting.
Our objectives were to:
• Determine whether plasma cardiac biomarker concentrations are associated with clinical progression to initiation of treatment with a potent diuretic or cardiac-related death in dogs with presumed stage B DMVD attending primary care veterinary practices.
• Evaluate whether physical examination findings and the presence or absence of clinical signs provide additional prognostic information to risk stratify affected animals. 
| MATERIALS AND METHODS

| Cox proportional hazard and flexible parametric models
The following explanatory (risk factor) variables were evaluated in the time-to-event analyses: age (years), body weight (kg), sex, neuter status, breed, evidence of insurance, plasma NT-proBNP concentration, plasma cTnI concentration, presence or absence of cough, dyspnea and exercise intolerance, heart rhythm, heart rate (beats per minute and the Schoenfeld residuals test of the assumption of PH. 14, 15 The predictive ability of the models was evaluated by Harrell's C concordance statistic. 14 Martingale residuals were used to assess the functional form of the relationship between continuous variables and outcome. 15 To identify outliers and individuals with disproportionate influence, deviance residuals and likelihood displacements measures were plotted, respectively.
14,15
Royston-Parmar flexible parametric models were used to predict survival probabilities and explore alternative approaches to modeling time-dependent effects (eg, where hazard ratios [HRs] for explanatory variables changed over time and did not meet the PH assumption). [16] [17] [18] Flexible parametric model selection was directed by model fit, which was assessed by graphical examination of different parametric distributions, the Akaike information criterion, and Bayesian information criterion. 17 Continuous variables were categorized in the multivariable parametric model for ease of interpretation and risk stratification.
Selection of explanatory variables was as described for the Cox regression models, although variables dependent on diagnostic imaging (eg, pimobendan administration) were excluded as the flexible parametric model was developed to evaluate whether dogs could be risk stratified using data routinely obtained from taking a history, performing a physical examination, and measuring cardiac biomarker concentrations. Clustering within veterinary practices was not evaluated because shared frailty terms cannot be included in flexible parametric models. Forward selection was used to identify whether explanatory variables included in the multivariable model had time-dependent effects. 17 After specifi- 
| Sample size calculation
A priori sample size calculations estimated that approximately 100 events would be required to detect a HR of 2 for a variable to which 20% of individuals were exposed, at a confidence level of 95% and power of 80%. Using data derived from the VetCompass database (data not shown), it was estimated that 650-700 dogs would need to be recruited to the study for over an 18-month accrual period and a minimum 6 months follow-up, assuming a 10% loss to follow-up. 19 3 | RESULTS
| Study population
Six-hundred and eighty-four dogs presumptively diagnosed with DMVD that did not receive a potent diuretic before or within 14 days after recruitment were included in the study. The breed most frequently recruited was the Cavalier King Charles Spaniel (CKCS; n = 231, 33.9%). The mean age at recruitment was 9.3 years (SD, 3.1 years) and the median body weight was 10.5 kg (IQR, 8.1-14.9 kg).
Three-hundred and seventy (54.3%) dogs were male ( The following explanatory variables had some evidence of an association (P < .2) with the outcome and were evaluated in multivariable Cox regression models: age, body weight, breed, insurance status, plasma NT-proBNP, plasma cTnI, presence of cough or dyspnea, heart rhythm, heart rate, heart murmur intensity, administration of pimobendan, administration of an ACE inhibitor, administration of spironolactone, and having a musculoskeletal disorder. In the multivariable model, higher concentrations of plasma NT-proBNP, presence of cough, higher heart murmur intensities and heart rates, receiving pimobendan, and being a CKCS were independently associated with clinical progression (Table 2 ). Variables included in the final multivariable model also had strong associations (P < .001) with the outcome in univariable analysis. The Schoenfeld residuals test was statistically significant, suggesting that the PH assumption was DMVD that were not CKCSs, with moderate intensity heart murmurs, heart rates <110 bpm, no cough, and NT-proBNP <900 pmol/L had a low risk of disease progression; 93.7% (95% CI, 89.9%-96.0%) of dogs with these characteristics were predicted not to start diuretics or die because of their heart disease during the next 12 months. In contrast,
for a hypothetical group of CKCSs with heart murmurs and thrills, heart rates >140 bpm, no cough, and NT-proBNP >1800 pmol/L, only 17.7% (95% CI, 4.6%-37.6%) were predicted not to reach these endpoints over the next 12 months.
| DISCUSSION
In our study, higher plasma NT-proBNP concentrations, heart rates and heart murmur intensities, being a CKCS, presence of cough, and receiving pimobendan were associated with a higher hazard of dogs with presumed stage B DMVD progressing to initiation of treatment with a potent diuretic or experiencing cardiac-related death. Although marginal evidence was found for an association between plasma cTnI concentration and clinical progression in the univariable analysis, insufficient evidence was found for an association in the multivariable analysis. In contrast, previous studies identified strong associations between cTnI and mortality in cohorts including dogs with CHF caused by DMVD. 10, 21, 23 The subset of dogs in our study was likely to represent a group with less severe cardiac disease (on average) than cohorts that also included dogs prescribed CHF treatment. Serial measurements of cTnI disclosed an increase in this biomarker within the 6 months preceding death in dogs that died because of their cardiac disease, 21 highlighting that cTnI is increased in the most advanced stages of DMVD. Because cTnI is not a specific biomarker for cardiac disease, the increase in this marker in presumed stage B dogs was possibly more likely to be a result of noncardiac causes than advanced cardiac disease, thus explaining a lack of association between cTnI and DMVD clinical progression in our study.
| Cardiac biomarkers
| Presenting signs, clinical findings, and signalment
Having a higher heart rate was associated with an increased hazard of presumed stage B dogs progressing to initiation of potent diuretic treatment or cardiac-related death. This finding concurs with previous studies that observed associations between increased heart rate and adverse cardiac outcome in dogs with preclinical DMVD. 2, 6 Moreover, studies evaluating the prognostic value of heart rate in dogs with a wider range of DMVD severity (including those diagnosed with CHF) 10, 21, 24, 25 reported that having a higher heart rate was associated with an increased hazard of adverse outcome. Although having an increased heart rate is associated with more advanced DMVD, 26 this finding is not specific for cardiac disease and can be influenced by a number of factors including emotional state and noncardiac disease. [27] [28] [29] In our study, dogs with heart murmur intensities grade III or above had a higher hazard of clinical progression than those with softer murmurs. This observation concurs with the findings of a randomized controlled trial that observed an association between higher heart murmur intensity and shorter time until developing CHF in CKCSs with preclinical DMVD. 7 In agreement, another study reported that CKCSs with heart murmur intensities ≥III/VI had an increased hazard of developing CHF than did those with lower intensity murmurs. 6 Moreover, heart murmur intensity has been found to correlate with DMVD disease severity 30, 31 and was associated with cardiac-related death in another cohort of dogs with DMVD attending a UK research clinic. 32 Dogs with higher intensity murmurs in our study thus might represent dogs with more advanced preclinical DMVD that were more likely to subsequently receive potent diuretics or die of their heart disease. Although descriptors of heart murmur intensity grades were provided on data collection forms, grading heart murmur intensity is subjective and can be influenced by factors such as body condition, emotional state, and how easy a dog is to auscultate. 33 Our study evaluated heart murmur intensity measured on a single occasion for each dog, thus analyses of intraobserver and interobserver variation were not performed.
The presence of cough also was associated with increased hazard of clinical progression. In agreement, a previous study reported an association between presence of cough at initial examination and subsequent progression of ACVIM-HD class in dogs with stage B DMVD. 5 Coughing can be triggered by bronchial compression as a result of atrial enlargement in more advanced preclinical DMVD, preceding the onset of CHF. 34 Alternatively, the observed association might have occurred if veterinarians elected to start treatment with a potent diuretic 
| Treatment
Pimobendan administration was associated with increased hazard of reaching the composite endpoint in our study. Strong evidence indicates that pimobendan is beneficial in extending survival in a subset of dogs with advanced preclinical DMVD and cardiomegaly confirmed by diagnostic imaging (ie, left atrial-to-aortic ratio ≥1.6, normalized left ventricular internal diameter in diastole ≥1.7, and vertebral heart sum >10.5). 2 Results of our study were therefore likely to reflect that pimobendan was more frequently prescribed to dogs with more advanced stage B DMVD and a worse prognosis. Echocardiographic and radiographic assessment of cardiac size currently is required to determine whether a dog would benefit from pimobendan. 2 This factor is reflected in our study, because exploratory analyses identified a strong association between pimobendan administration and undergoing diagnostic imaging in presumed stage B dogs (Chi squared test, P < .001). Because we aimed to identify the predictive value of factors not dependent on diagnostic imaging, pimobendan administration was excluded from the flexible parametric model.
| General strengths and limitations
Our study used a prospective cohort design to provide further insights into factors associated with disease progression in dogs with presumed stage B DMVD. Several clinical measurements identified in our study (NT-proBNP, heart rate, and heart murmur intensity) also were predictive of mortality in cohorts of dogs with different stages of DMVD, 10, 21, 25, 32, 35 supporting the prognostic value of these measure- because of DMVD. 10, 21, 23 This is consistent with the findings of another study, in which NT-proBNP measurements increased at an earlier stage in the natural progression of the disease than did circulating cTnI. 21 The predictions derived from the flexible parametric model highlight that using information from a number of factors is more informative when forming a prognosis than measuring a single factor. The prognostic factors identified in our study, therefore, should be evaluated in combination rather than in isolation. Risk stratification based on disease severity could facilitate decision-making and advice to owners when managing dogs with DMVD in practice. 2, 21 For example, dogs identified as having more advanced presumed stage B DMVD might receive the greatest benefit from further diagnostic investigations and subsequent treatment, whereas a "watch and wait" approach might be more appropriate for a dog belonging to a low risk To allow the results of our study to be applied to settings in which diagnostic imaging is not routinely performed, echocardiographic confirmation of the presumptive DMVD diagnosis was not an inclusion criterion. It is therefore possible that dogs erroneously diagnosed with DMVD were included in our study. However, participating clinicians were provided with information on typical presentation and risk factors for DMVD to improve the accuracy of presumptive diagnoses and recruited cases largely consisted of small to medium-sized older dogs, a population known to have a high prevalence of DMVD. 36, 37 Moreover, the breed, body weight, and age distributions of the dogs in our study were similar to those reported in previous studies restricted to dogs with DMVD confirmed by echocardiography. 21, 32 Our study included dogs that were not receiving potent diuretics at recruitment and that were assumed to have stage B DMVD, defined as "patients with structural heart disease (e.g. the typical murmur of mitral valve regurgitation is present), but that have never developed clinical signs caused by heart failure." 1 Because potent diuretics are essential for dogs with CHF, 1 it is unlikely that dogs included in our study had stage C or D DMVD at recruitment. However, the rationale behind prescribing diuretics was not explored and some dogs without CHF may have been inappropriately prescribed diuretics and excluded from the study. procedure was not consistently undertaken before initiating diuretic treatment, and starting treatment with a potent diuretic was based on the clinicians' perceptions of heart disease progression in many cases.
Radiographic confirmation of CHF would have improved the validity of the results, but the lack of these data reflects the reality of primary care practice. Another UK study also reported that diagnostic imaging was not undertaken often when evaluating dogs with suspected CHF in primary care practice. 39 It is unclear why thoracic radiography was not performed more frequently in these cases, and future research exploring clinical decision making when managing dogs with DMVD and the reliability of CHF diagnoses in primary care practice is warranted. Factors that may deter clinicians from performing thoracic radiographs might include owner inability to pay for diagnostic tests and a reluctance to sedate uncooperative patients for radiography in a country where manual restraint for radiography is discouraged. Finally, relevant treatment data might not be captured in EPRs if owners obtained diuretics from online pharmacies or other veterinary practices. However, despite limitations relating to the outcome, several key findings were consistent with those reported in previous studies that used radiography to assess clinical progression in dogs with preclinical DMVD.
2-4,6,7
Our results cannot be used to differentiate stages B1 and B2 DMVD, or be used to make treatment recommendations. However, it might be possible to develop a scoring system based on variables obtained from routine history, physical examination, and cardiac biomarker concentrations to help distinguish between the preclinical stages of DMVD and even potentially select animals that are most likely to benefit from treatment. 40 The prognostic variables identified in our study, that are likely to reflect more advanced disease, could be worthy candidates to evaluate in such work.
As described above, it is unclear whether the evaluated composite endpoint was a reliable proxy for advancing DMVD. The observed associations between explanatory variables and the outcome could have arisen if veterinarians elected to start treatment with a potent diuretic because of preconceptions relating to breed predispositions, historical, or physical examination findings (eg, the presence of cough and high intensity murmur), rather than these factors being predictive of future disease progression. Validation of the prognostic model in a different population would therefore be of value, 17 particularly if disease progression was supported by diagnostic imaging in an independent test set.
In conclusion, data obtained from taking a history and performing a physical examination could be used in combination with NT-proBNP concentrations to risk stratify dogs with presumed stage B DMVD managed by primary care practitioners. Dogs identified as having a high risk of disease progression might benefit from more frequent monitoring, further diagnostic evaluation, or referral to a veterinary cardiologist. 
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